Advertisement

Hypertension

Part of the Contemporary Cardiology book series (CONCARD)

Abstract

There are more than one billion individuals with hypertension worldwide, bdand only four classes of antihypertensive agents are available.
  • More than 60 million Americans, 20% of the population, have hypertension that requires drug therapy. At age 65–75, however, more than 60% of individuals have hypertension. The incidence is higher in blacks. The prevalence of hypertension in industrialized countries in general is similar to that in the white population of the United States. Hypertension is the most common indication both for visits to physicians and for the use of prescription drugs in the United States.

  • Most important, we only have four groups of drugs (diuretics, beta-blockers, angiotensinconverting enzyme (ACE) inhibitors, or angiotensin 11 receptor blockers (ARBs) and calcium antagonists) to treat this most common condition that leads to devastating events, particularly death and disability. I have purposely left out centrally acting agents (methyldopa and clonidine) and alpha-blockers because their use is limited to a few selected individuals.

  • At the onset of my discussions, I must emphasize that ACE I/ARBs are excellent, well-tested, but mild antihypertensive agents, and that calcium antagonists are the most powerful of the four antihypertensive agents available for management of moderate and severe hypertension. We would be lost if these agents were not part of our antihypertensive armamentarium.

  • ACE inhibitors and the identically acting ARBs are a major advance but represent a single class of agent.

Keywords

Ischemic Heart Disease Calcium Antagonist Antihypertensive Agent Systolic Hypertension Target Organ Damage 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Khan M Gabriel. Hypertension. In: Cardiac Drug Therapy, London, WB Saunders, 1988.Google Scholar
  2. 2.
    The ALLHAT Officers and Coordinators for the ALLH AT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2000;283:1967–1975.CrossRefGoogle Scholar
  3. 3.
    Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med 1997;157:2413.Google Scholar
  4. 4.
    SHEP Cooperative Study Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: Final results of the Systolic Hypertension in Elderly Programs (SHEP). JAMA 1991;265:3255.CrossRefGoogle Scholar
  5. 5.
    Staessen J A, Wang Ji-Guang, Thijs L. Cardiovascular protection and blood pressure reduction: A metaanalysis. Lancet 2001;358:1305.PubMedCrossRefGoogle Scholar
  6. 6.
    Materson B J, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men: A comparison of six antihypertensive agents with placebo. N Engl J Med 1993;328:914.PubMedCrossRefGoogle Scholar
  7. 7.
    HANE: Philipp T, Anlauf M, Distler A, et al. on behalf of the HANE trial research group: Randomised double blind, multicentre comparison of hydrochlorothiazide, atenolol, nitrendipine, and enalapril in antihypertensive treatment: Results of the HANE study. BMJ 1997;315:154.PubMedGoogle Scholar
  8. 8.
    CAPRICORN Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: The CAPRICORN randomized trial. Lancet 2001;357:1385.CrossRefGoogle Scholar
  9. 9.
    COPERNICUS: Packer M, Coats JS. Fowler MB, et al. for the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group: Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344;1651.PubMedCrossRefGoogle Scholar
  10. 10.
    INSIGHT: Brown MJ, Christopher RP, Castaigne A. Morbidity and mortality in patients randomized to double blind treatment with a long acting calcium channel blocker or diuretic in the international nif edipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000;356:366.PubMedCrossRefGoogle Scholar
  11. 11.
    PRAISE: Packer M, O’Connor CM, Ghali JK, et al. for the Prospective Randomized Amlodipine Survival Evaluation (PRAISE): Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996;335:1107.PubMedCrossRefGoogle Scholar
  12. 12.
    Multicenter Diltiazem Postinf arction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988;319:385CrossRefGoogle Scholar
  13. 13.
    Dahlof B, Lindholm LH, Hansson L, et al. Morbidity and mortality in the Swedish Trial in Old Patients with hypertension (STOP hypertension). Lancet 1991;338:1281.PubMedCrossRefGoogle Scholar
  14. 14.
    Materson BJ, Reda D, Freiss ED, Henderson WG. Cigarette smoking interferes with treatment of hypertension. Arch Intern Med 1988;148:2116.PubMedCrossRefGoogle Scholar
  15. 15.
    BHAT: β-Blocker Heart Attack Trial Research Group. A randomised trial of propranolol in patients with acute myocardial infarction, I: mortality results. JAMA 1982;247:1707–1714.CrossRefGoogle Scholar
  16. 16.
    Norwegian Multicentre Study Group. Timolol-induced reduction in mortality in reinf arction in patients surviving acute myocardial infarction. N Engl J Med 1981;304:801.CrossRefGoogle Scholar
  17. 17.
    Casas JP, Chau W, Loukogeorgakis S, et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: Systematic review and meta-analysis. Lancet 2005;366: 2026–2033.PubMedCrossRefGoogle Scholar
  18. 18.
    PROGRESS Collaborative Group. Randomized trial of a perindopril-based blood pressure lowering regimen among, individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033.CrossRefGoogle Scholar
  19. 19.
    Khan M Gabriel. Aortic dissection. In: Heart Disease Diagnosis and Therapy, a Practical Approach, 2nd ed. Totowa, NJ, Humana Press, 2005, p. 369.Google Scholar
  20. 20.
    The Seventh Report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. JAMA 2003;289:2560–2572.Google Scholar
  21. 21.
    The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major out-comes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981–2997.CrossRefGoogle Scholar
  22. 22.
    UKPDS: UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes. BMJ 1998;317:713.Google Scholar
  23. 23.
    Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project. Lancet 1999;353:611–616.PubMedCrossRefGoogle Scholar
  24. 24.
    Mangano DT, Layug EL, Wallace A, et al. Effect of atenolol on mortality and cardiovascular morbidity after non-cardiac surgery. N Engl J Med 1996;335:1713.PubMedCrossRefGoogle Scholar
  25. 25.
    Devereux RB. Do antihypertensive drugs differ in their ability to regress left ventricular hypertrophy? Circulation 1985;95:1983.Google Scholar
  26. 26.
    Dunn FG, Venture HO, Messerli FH, et al. Time course of regression of left ventricular hypertrophy in hypertensive patients treated with atenolol. Circulation 1987;76:243.Google Scholar
  27. 27.
    Clark JA, Zimmerman HF, Tanner LA. Labetalol hepatotoxicity. Ann Intern Med 1990;113:210.PubMedGoogle Scholar
  28. 28.
    Felson DT, Sloutskis D, Anderson J, et al. Thiaxide diuretics and the risk of hip fracture. JAMA 1991; 265:370.Google Scholar
  29. 29.
    LaCroix AZ, Wienpahl J, White LR, et al. Thiazide diuretic agents and the incidence of hip fracture. N Engl J Med 1990;322:288.CrossRefGoogle Scholar
  30. 30.
    Ray WA, Griffin Downey W. Long-term use of thiazide diuretics and risk of hip fracture. Lancet 1989; 1: 687.PubMedCrossRefGoogle Scholar
  31. 31.
    Magee PF, Freis ED. Is low-dose hydrochlorothiazide effective? Hypertension 1986;8:III35.Google Scholar
  32. 32.
    Siscovick DS, Raghanathan TE, Psaty BM, et al. Diuretic therapy for hypertension and the risk of primary cardiac arrest. N Engl J Med 1994;330:1852.PubMedCrossRefGoogle Scholar
  33. 33.
    Biron P, Dessureault J, Napke E. Acute allergic interstitial pneumonitis induced by hydrochlorothiazide. Can Med Assoc J 1991;145:28.Google Scholar
  34. 34.
    Hoegholm A, Rasmussen SW, Kristensen KS. Pulmonary oedema with shockinduced by hydrochlorothiazide: A rare side effect mimicking myocardial infarction. Br Heart J 1990;63:186.PubMedCrossRefGoogle Scholar
  35. 35.
    Caskey FJ, Thacker EJ, Johnston PA, et al. Failure of losartan to control blood pressure in scleroderma renal crisis. Lancet 1997;349:620.PubMedCrossRefGoogle Scholar
  36. 36.
    Hommel E, Parvin Hans H, Mathiesen E, et al. Effect of captopril on kidney function in insulin-dependent diabetic patients with nephropathy. BMJ 1986;293:467.PubMedCrossRefGoogle Scholar
  37. 37.
    Taguma Y, Kitamoro Y, Futaki G, et al. Effect of captopril on heavy proteinuria in azotemic diabetics. N Engl J Med 1985;313:1617.PubMedCrossRefGoogle Scholar
  38. 38.
    Jenkins AC, Dreslinski GR, Tadros SS, et al. Captopril in hypertension: Seven years later. J Cardiovasc Pharmacol 1985;7:596.CrossRefGoogle Scholar
  39. 39.
    Hricik DE, Browning PJ, Kopelman R, et al: Captopril-induced functional renal insufficiency in patients with bilateral renal-artery stenoses or renal-artery stenosis in a solitary kidney. N Engl J Med 1983;308: 373.PubMedCrossRefGoogle Scholar
  40. 40.
    Greminger P, Vetter H, Steurer T, et al. Captopril and kidney function in renovascular and essential hypertension. Nephron 1986;4(Suppl 1):91.Google Scholar
  41. 41.
    Topol EJ, Thomas AT, Fortuin NJ. Hypertensive hypertrophic cardiomyopathy of the elderly. N Engl J Med 1985;312:277.PubMedCrossRefGoogle Scholar
  42. 42.
    Leary WP, Reyes AJ. Angiotensin I converting enzyme inhibitors and the renal excretion of urate. Cardiovasc Drugs Ther 1987;1:29.PubMedCrossRefGoogle Scholar
  43. 43.
    Chimori K, Miyazaki S, Nakajima T, et al. Preoperative management of pheochromocytoma with the calcium antagonist nifedipine. Clin Ther 1985;7:372.PubMedGoogle Scholar
  44. 44.
    Bursztyn M, Tordjman K, Grossman E, et al. Hypertensive crisis associated with nifedipine withdrawal. Arch Intern Med 1986;146:397.PubMedCrossRefGoogle Scholar
  45. 45.
    Binder EF, Cayabyab L, Ritchie DJ, et al. Diltiazem-induced psychosis and a possible diltiazem-lithium interaction. Arch Intern Med 1991;151:373.PubMedCrossRefGoogle Scholar
  46. 46.
    NORDIL: Hansson L, Hedner T, Lund-Johansen P, et al. Randomized trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: The Nordic Diltiazem study. Lancet 2000;356:359.PubMedCrossRefGoogle Scholar
  47. 47.
    Seeverens H, deBruin CD, Jordans JGM. Myocarditis and methyldopa. Acta Med Scand 1982;211–233.Google Scholar
  48. 48.
    Wright JT Jr, Wilson DJ, Goodman RP, et al. Labetalol fay continuous infusion in severe hypertension. J Clin Hypertens 1986;2:39.PubMedGoogle Scholar
  49. 49.
    Murphy MB, Murray C, Shorten G. Fenoldopam: A selective peripheral dopamine-receptor agonist for the treatment of severe hypertension: Review article. N Engl J Med 2001;345:1548.PubMedCrossRefGoogle Scholar

Suggested Reading

  1. 50.
    Brook RD. How to achieve control in managing hypertension. J Am Coll Cardiol Curr Rev May/June:35, 2002.Google Scholar
  2. 51.
    ALLHAT: Davis BR, Piller LB, Cutler JA, et al. for the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Collaborative Research Group. Role of diuretics in the prevention of heart failure: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Circulation 2006;113:2201–2210.PubMedCrossRefGoogle Scholar
  3. 52.
    Grossman E, Messerli FH. The management of hypertensive crisis. Am Coll Cardiol Curr J Rev Jan/Feb, 1999.Google Scholar
  4. 53.
    Gueffier F, Bulpitt C, Biossel JP, et al. for the INDIANA GROUP. Antihypertensive drugs in very old people: A subgroup meta-analysis of randomized controlled trials. Lancet 1999;353:793.CrossRefGoogle Scholar
  5. 54.
    Materson BJ, Reda DJ. Correction: single-drug therapy for hypertension in men. N Engl J Med 1994;330: 1689.PubMedCrossRefGoogle Scholar
  6. 55.
    Messerli FH, Re RN. Do we need yet another blocker of the renin-angiotensin system? J Am Coll Cardiol 2007;49:1164–1165.PubMedCrossRefGoogle Scholar
  7. 56.
    Murphy MB, Murray C, Shorten G. Fenoldopam—a selective peripheral dopamine-receptor agonist for the treatment of severe hypertension: Review article. N Engl J Med 2001;345:1548.PubMedCrossRefGoogle Scholar
  8. 57.
    Oh Byung-Hee, Mitchell J, Herron JR, et al. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-h blood pressure control in patients with hypertension. J Am Coll Cardiol 2007;49: 1157–1163.PubMedCrossRefGoogle Scholar
  9. 58.
    Rahman M, Pressel S, Davis BR, et al. for the ALLHAT Collaborative Research Group. Cardiovascular out-comes in high-risk hypertensive patients stratified by baseline glomerular filtration rate. Ann Inter Med 2006;144:172–180.Google Scholar
  10. 59.
    Yusuf S. Preventing vascular events due to elevated blood pressure. Circulation 2006;113:2166–2168.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc., Totowa, NJ 2007

Personalised recommendations